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Abstract 
As a regulator of coagulation, abnormal Protein Z (PZ) expression may lead to the formation of blood clots in humans. 
While previous studies have shown that PZ protein is altered in several types of cancer, however, additional observa‑
tions are needed to understand the complex biology involved. Herein, we investigated local alterations in PZ expres‑
sion in lung adenocarcinomas by measuring gene and protein expression in both cancerous and normal lung tissues. 
Twenty‑two (22) specimens of lung adenocarcinoma and 22 specimens of normal lung tissues from human patients 
were compared for the expression of PZ. In addition, A549 adenocarcinoma cells were compared to a normal epithe‑
lial cell line, 16‑HBE, for in vitro PZ expression. In tissues and cells, PZ protein and gene expression were determined 
using western blot, immunohistochemistry and PCR. Lung adenocarcinoma tissues showed elevated expression of 
both PZ mRNA and protein compared with healthy tissue. Only protein expression was increased in cultured cell lines, 
which holds implications for the dominant source of PZ in tissues, as well as protein modifications necessary for PZ 
function. Protein Z appears to be associated with the presence of lung adenocarcinoma and may be a viable prog‑
nostic biomarker for lung cancer.
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Background
Protein Z (PZ) is a vitamin K-dependent (VKD) glycopro-
tein that acts as a potent cofactor for the enzyme protein 
Z-dependent protease inhibitor (ZPI). Together, these 
proteins mediate thrombin activation and blood coagu-
lation by strongly inhibiting the activation of Factor Xa 
(FXa). PZ shares structural similarities with other VKD 
factors such as coagulation factor VII, IX, X, protein C 
and protein S, but holds no intrinsic enzymatic activity 
(Broze and Miletich 1984). While the specific mecha-
nism of PZ’s actions in the anticoagulation cascade is not 
established, several reports demonstrate the formation of 
a PZ/ZPI complex that inactivates FX, thereby inhibiting 
the coagulation cascade prior to formation of the pro-
thrombin complex. In fact, the presence of PZ enhances 
the inhibition of FXa by ZPI by 1000-fold (Fujimaki et al. 
1998). In this regard, the traditional role of PZ in mediat-
ing anticoagulation is to serve as a critical factor in ZPI 
and FX signaling (Tabatabai et al. 2001), ultimately con-
trolling thrombus formation.
Thromboembolisms are one of the most common ail-
ments in cancer patients, as many hemostatic complica-
tions can arise due to malignancy (Wojtukiewicz et  al. 
2001). An imbalance in pro- and anti-coagulation factors 
may lead to blood coagulation abnormalities and vas-
cular disorders, which could further exacerbate cancer 
progression, as well as attenuate immunologic defense 
mechanisms and therapeutic efficacy of chemothera-
peutic drugs and other treatments (Sierko et  al. 2012b; 
Wojtukiewicz et  al. 2007). The activation of FX has 
been considered the most important step leading to the 
formation of thrombin and fibrin in both normal and 
pathologic conditions (Bick 1992; Falanga and Rickles 
1999; Zacharski et al. 1992). However, it remains unclear 
whether disruption of inhibition of FXa by PZ/ZPI spe-
cifically underlies the pathogenesis of thrombosis and 
other blood coagulation disorders in cancer patients. Our 
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previous studies have found that as malignant tumors 
progress, plasma levels of PZ significantly decrease 
(Shang et al. 2005), which indicates that PZ may be a fac-
tor contributing to poor prognosis in cancer patients. It 
remains unclear, however, whether circulating concentra-
tions or local tissue PZ expression is primarily responsi-
ble for the downstream increase in thrombotic episodes 
in patients. Abnormal tissue expression of PZ has been 
observed in human cancers of the lung, breast, colon, and 
stomach (Sierko et al. 2011, 2012a, b, 2014). Interestingly, 
patients with these types of cancers are also more prone 
to developing thrombosis.
Determining mechanisms by which local changes in 
a tumor microenvironment lead to systemic changes in 
an individual is an important aim in cancer research. In 
the current study, we investigate PZ expression in lung 
adenocarcinomas, which is highly metastatic and likely 
to cause the development of thrombosis. We examined 
the expression of PZ in cell cultures and in lung adeno-
carcinoma biopsies using Western blotting, immunohis-
tochemistry, and RT-PCR to observe any differences in 




This study protocol adhered to the principles of Hel-
sinki and was confirmed by the ethics committee of the 
First Affiliated Hospital of Guangdong Pharmaceuti-
cal University. A total of 22 specimens were collected 
from pathologically-confirmed lung adenocarcinoma 
patients who underwent surgery in the Thoracic 
Department of the First Affiliated Hospital of Guang-
dong Pharmaceutical University between 2008 and 
2011. Informed consent was obtained from all subjects 
before the study. The average age of the patients was 59, 
with 12 males and 10 females ranging from 27–80 years 
old. The cancerous tissue was collected from a primary 
lesion, avoiding the necrotic and inflammatory sites, 
while normal lung tissues were collected  >5  cm, away 
from the corresponding lesion. Upon surgical removal, 
all specimens (0.5 cm × 0.5 cm × 0.2 cm) were imme-
diately frozen in liquid nitrogen and stored at −80  °C 
until use.
Cell culture
Human bronchial epithelial 16-HBE cells and a lung 
adenocarcinoma epithelial cell line, A549, were pro-
vided by the Experimental Medical Research Center at 
the Guangzhou Medical University. Cells were grown in 
DMEM supplemented with 10 % FBS at 37 °C in 5 % CO2 
and passaged twice. Cultures with a density of 5 × 105/ml 
were used for all experiments.
Primer design
Primers were designed using Primer 6.0 software, synthe-
sized by Sangon Biotech (Shanghai, China), and ampli-
fied a 159 bp product. Sequences are shown in Table 1.
Tissue RNA extraction
Total RNA was extracted according to the manufacturer’s 
instructions using TRIzol reagent, and precipitated RNA 
was dissolved in 50  μl DEPC-treated water. Agarose gel 
electrophoresis showed three clear bands at 5, 18, and 
28S. The absorbance of RNA samples at 260 and 280 nm 
was determined using UV spectroscopy and only samples 
with A260/A280 ratio between 1.8 and 2.0 were used for 
reverse transcription.
qRT‑PCR
cDNA was synthesized with 4 μl total RNA using the Pri-
meScript TM RT Master Mix Kit (Takara) according to 
the manufacturer’s instructions. Primer sets for PZ and 
GAPDH are listed in Table  1 (see “Primer design” sec-
tion). By using a real time PCR machine (MX3000P, Strat-
agene, USA), PCR reactions were performed in a total of 
20  μl reaction volume containing 10  μl 2 ×  Mix, 0.4  μl 
50 × Rox, 3 μl (F + R) primer (2 μmol/L), 1 μl cDNA, and 
distilled water to make up to 20  μl. The thermocycling 
conditions were as follows: 30 s at 95 °C, followed by 40 
cycles of 5 s at 95 °C, 30 s at 56 °C, and ended with 30 s 
at 72  °C. The quantification of gene expression changes 
were calculated as follows: (1) fold change = 2 − ΔΔCt; 
(2) ΔΔCt  =  ΔCt treatment group  −  ΔCt control 
group = (CT target gene − CT reference gene) treatment 
group −  (CT target gene −  CT reference gene) control 
group.
Immunohistochemistry
Immunohistochemical analysis was performed using 
the Histostain-SP IHC Kit (Life Technologies) accord-
ing to the manufacture’s protocol. Briefly, tissue samples 
were fixed in 10  % formalin, dehydrated, and paraffin-
embedded. Paraffin blocks were cut for 4 μm-thick serial 
sections, and antigen retrieval was performed by micro-
waving in a pH 8.0 sodium citrate solution. Monoclonal 
mouse anti-human PZ antibody (Abcam, UK) (1:1600) 
was used as primary antibody, followed by incubation 
with ALP-conjugated goat anti-mouse IgG (1:5000), and 
DAB was used as the chromogen. PZ-positive cells were 
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defined as cells with brown precipitates in the plasma. 
Cells without staining were marked as negative (−); cells 
stained light brown were marked as weakly positive (+); 
cells stained dark brown were marked as strongly positive 
(+++); and cells stained between weakly and strongly 
positive were marked as moderately positive (++). 
Staining was scored using a 13-point scoring system 
(Sierko et  al. 2014) based on the percentage of stained 
cells (no cells stained  =  0,  <10  %  =  1, 10–50  %  =  2, 
51–80 % = 3, >80 % = 4) and the intensity of the stain-
ing (negative staining = 0, weak staining = 1, moderate 
staining  =  2, strong staining  =  3). The final score was 
determined by multiplying the percentage of positively 
stained cell score with the intensity score (see Table 2 for 
a summary). All results were analyzed by two observers 
that were blinded to the condition of the patients.
Western blotting
Total protein was extracted from the frozen tissue sam-
ples using ultrasound homogenization with SDS lysis 
buffer (Beyotime Biotechnology, China). Lysates were 
cleared by centrifugation at 4  °C. The collected super-
natants were measured for protein concentration using 
a BCA protein assay before being separated on 10  % 
SDS-PAGE gels and transferred to PVDF membranes. 
The membranes were incubated overnight at 4  °C with 
anti-PZ antibody (Abnova Taiwan, 1:2500) in PBS with 
1 %BSA. The next day, membranes were washed and then 
incubated for 2  h at room temperature with ALP-con-
jugated secondary antibody (1:20,000). Protein signals 
were detected using NBT/BCIP (Beyotime Institute of 
Biotechnology) and analyzed with IPP software. The PZ/
actin ratio was used for statistical analysis.
Statistical analysis
All data are expressed as mean ± standard deviation. Sta-
tistical analysis was performed using SPSS 19.0 by T test, 
and p value <0.05 was considered statistically significant.
Results
mRNA expression of PZ gene in cells
We used SYBR-based quantitative fluorescence PCR to 
detect the expression of PZ gene in the A549 lung ade-
nocarcinoma cell line and 16-HBE normal epithelial line, 
using GADPH to normalize the samples. The dissociation 
curves for both genes showed a single peak, suggesting 
that no off-target products, such as primer dimers, were 
formed. A549 adenocarcinoma cells exhibited a 1.06-fold 
increase in PZ mRNA expression over 16-HBE cells, but 
this increase was not statistically significant (Fig. 1).
mRNA expression of PZ in human lung adenocarcinoma 
tissue samples
Similarly, we used SYBR-based quantitative fluorescence 
PCR to detect the genetic expression of PZ in 22 lung 
adenocarcinoma and 22 normal tissues. A single peak 
was again observed, indicating that no off-target prod-
ucts such as primer dimers were formed. Compared with 
normal tissue, PZ mRNA expression was 1.77-fold higher 
in lung adenocarcinoma samples, which was statistically 
significant (Fig. 2).
Immunohistochemical analysis of PZ in human lung 
adenocarcinoma tissue samples
The expression of PZ in cancerous lung tissue was 
increased, as indicated by intense brown staining in 
Fig. 3a. In contrast, healthy lung tissues showed minimal 
expression of PZ (Fig. 3c). Overall, PZ protein appears to 
be expressed in macrophages and endothelial cells in the 
newly formed vessels, which is in line with previous find-
ings (Sierko et al. 2012b).
Protein expression of PZ in A549 and 16‑HBE cells
As shown in Fig. 4, western blot analysis shows a signifi-
cant 1.84-fold higher expression of PZ protein in A549 
cells than 16-HBE epithelial cells. This suggests that the 
expression level of PZ protein may be associated with 
Table 2 Immunohistochemical results of PZ in lung adeno-





Proportion of positive cells (%) >75 <25
Staining scores 58 9
Staining results 22/22 (100 %) 7/22 (31 %)
Fig. 1 PZ mRNA in cell cultures. In comparison with normal cells, 
A549 adenocarcinoma cells exhibited a 1.06‑fold increase in PZ mRNA 
expression. (P = 0.086)
Page 4 of 7Wang et al. SpringerPlus  (2016) 5:1046 
cancerous cells. Furthermore, this change is likely to be 
mediated by post-transcriptional or post-translational 
modifications, as total PZ mRNA expression was mini-
mally altered (Fig. 4).
Protein expression of PZ in lung adenocarcinomas 
and healthy lung tissues
We next examined the expression of PZ protein in 22 
lung adenocarcinoma and 22 healthy lung tissues via 
western blotting. Representative images of the mem-
branes shown in Fig. 5 illustrate that PZ expression is sig-
nificantly increased in cancerous tissues compared with 
normal lung tissue.
Discussion
In order to examine whether protein Z (PZ) is altered 
in primary cancer tissues, we studied PZ expression in 
human lung adenocarcinomas, one of the most meta-
static and thrombosis-prone lung cancers. Using Western 
blotting, immunohistochemical staining and real-time 
PCR techniques, we examined the expression levels of 
PZ in lung adenocarcinoma versus normal lung tissue. 
Our results show increased expression of PZ in lung 
adenocarcinoma tissues and higher expression in A549 
than 16-HBE, which correlates with previous experimen-
tal results that provide a role for local PZ expression in 
the biology of several types of cancer (Sierko et al. 2011, 
2012a, b, 2014). Although additional studies are needed, 
these results indicate that altered PZ expression plays a 
role in the local pathobiology of lung cancer, possibly dis-
tinct from its global role as an anti-coagulant.
Thromboembolisms are commonly associated with 
cancer malignancy, as global hemostatic changes are 
observed in response to tumor formation and growth. 
Thrombin and fibrin are largely known for their essen-
tial roles as coagulants in the blood. However, these and 
other related pro-coagulants, such as tissue factor and 
Factor X, have strong effects on cell biology aside from 
blood clot formation. Thrombin, for example, stimu-
lates cancer cell proliferation and migration (Bick 1992; 
Zacharski et  al. 1992), and acts on endothelial cells to 
stimulate angiogenesis and vascular permeability (Woj-
tukiewicz et  al. 2001). Fibrin can act as a scaffold for 
balancing mechanical tension during tumor growth, or 
to bind growth factors that guide cell behavior or are 
released upon fibrin degradation (Zacharski et al. 1992).
Often, an increase in the expression of coagulation fac-
tors naturally leads to an increase in the expression of 
their inhibitors, which includes PZ (Sierko et al. 2012b). 
While evidence of direct effects of PZ on different cell 
types is minimal, studies have demonstrated a role for PZ 
in normal angiogenesis (Butschkau et al. 2014), accumu-
lation of PZ around vascular lesions (Greten et al. 1998) 
and increased PZ expression surrounding blood vessels 
in breast cancer tissue (Sierko et  al. 2011), all of which 
indicate a more direct involvement of PZ in endothelial 
and mural cell biology. Maintaining a balance between 
pro- and anti-coagulant factors is, therefore, not only 
critical for blood clot formation and degradation, but also 
for proper cellular activation and homeostasis within tis-
sues themselves.
A relationship between PZ and cancer has been 
observed, but experimental results are conflicting and 
generally inconclusive. In liver cancer, it was found that 
PZ might serve as a tumor suppressor (Neumann et  al. 
2012). In acute leukemia, reduced plasma PZ levels 
were shown to increase the risk of bleeding in patients 
(Galar et al. 2012). Another recent study reported a sig-
nificant drop of plasma PZ level in young acute lympho-
blastic leukemia (ALL) patients undergoing induction 
therapy; however, this decrease did not correlate with 
bleeding or thrombosis (Cankal et  al. 2013), indicat-
ing non-traditional roles for PZ in cancer cell biology. 
Sierko et al. recently showed an overexpression of PZ in 
breast, lung, colon, and stomach cancer tissues (Sierko 
Fig. 2 PZ mRNA in normal vs. cancerous tissue biopsies. Compared 
to normal tissue, PZ mRNA expression was 1.77‑fold higher in lung 
adenocarcinoma tissue, which was statistically significant (P = 0.023). 
The altered PZ expression in adenocarcinoma patient samples, com‑
pared with normal tissues, suggests its involvement in the pathology 
of lung adenocarcinoma
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et  al. 2011, 2012a, b, 2014). Additionally, they detected 
elevated PZ expression in tissue-associated macrophages 
and endothelial cells in cancer microenvironments, and 
examined the expression and interactions of PZ, ZPI, 
prothrombin fragments (F1 + 2), and fibrin in non-small-
cell lung carcinoma and colon cancer (Sierko et al. 2011, 
2012a, b). Their findings suggest that PZ, through its 
anticoagulation properties, affects tumor angiogenesis, 
invasion and metastasis. On the other hand, our previ-
ous clinical studies have found that as a malignant tumor 
progresses, circulating levels of PZ significantly decrease 
(Broze and Miletich 1984). While this may seem conflict-
ing to the data presented here and by others (Sierko et al. 
2011, 2012a, b, 2014), it could simply mean that certain 
components of tumor (and tissue) microenvironments 
may not be properly represented in the circulation, and 
care should be taken during the establishment of truly 
representative novel circulating biomarkers.
Conclusions
The current study confirms that PZ is locally present 
in lung adenocarcinomas. Given what is known about 
the biology of PZ, it may play a critical role in the 
tumor microenvironment, or in the systemic response 
to maintain homeostasis. We provide evidence that 
PZ should be studied to determine its distinct roles in 
tumor initiation, progression, angiogenesis and meta-
static potential. It is possible that PZ may serve as an 
important target for treatments of lung adenocarcino-
mas and other tumors, and more experiments will help 
Fig. 3 Representative images from immunohistochemical staining. In lung adenocarcinoma tissue (a), an increase in PZ staining (brown) is 
observed. The black arrow indicates the cytoplasmic expression of PZ, while the red arrow and yellow arrow indicates the presence of PZ protein in 
macrophages and endothelial cells, respectively. Scale bar 50 μm. b PZ protein was not expressed in the cytoplasm of cells in healthy lung tissue. 
The positively stained cells are macrophages (red arrow) and endothelial cells (yellow arrow). Scale bar 50 μm
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to determine the precise role of PZ in disease pathogen-
esis and progression.
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